|
Kolwankar, Dhanashri; Vuppalanchi, Raj; Ethell, Brian et al. (2007) Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 5:388-93
|
|
Jones, David R; Ekins, Sean; Li, Lang et al. (2007) Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos 35:1466-75
|
|
Pinto, A G; Horlander, J; Chalasani, N et al. (2005) Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 59:440-6
|
|
Pinto, Amar G; Wang, Ying-Hong; Chalasani, Naga et al. (2005) Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 77:178-88
|
|
Ernest 2nd, C Steven; Hall, Stephen D; Jones, David R (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-91
|
|
Gorski, J Christopher; Vannaprasaht, Suda; Hamman, Mitchell A et al. (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-87
|
|
Belle, Donna J; Callaghan, John T; Gorski, J Christopher et al. (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67-74
|
|
Asghar, Ali; Gorski, J Christopher; Haehner-Daniels, Barbara et al. (2002) Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos 30:20-6
|
|
Hamman, M A; Bruce, M A; Haehner-Daniels, B D et al. (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-21
|
|
Bruce, M A; Hall, S D; Haehner-Daniels, B D et al. (2001) In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 29:1023-8
|
Showing the most recent 10 out of 19 publications
